0001062993-23-001274.txt : 20230123
0001062993-23-001274.hdr.sgml : 20230123
20230123194928
ACCESSION NUMBER: 0001062993-23-001274
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230123
DATE AS OF CHANGE: 20230123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lake Ryan David
CENTRAL INDEX KEY: 0001450325
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36329
FILM NUMBER: 23545596
MAIL ADDRESS:
STREET 1: KENSEY NASH CORPORATION
STREET 2: 735 PENNSYLVANIA DRIVE
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Societal CDMO, Inc.
CENTRAL INDEX KEY: 0001588972
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261523233
STATE OF INCORPORATION: PA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 E. UWCHLAN AVE, SUITE 112
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 770-534-8239
MAIL ADDRESS:
STREET 1: 1 E. UWCHLAN AVE, SUITE 112
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: Recro Pharma, Inc.
DATE OF NAME CHANGE: 20131010
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2023-01-19
0001588972
Societal CDMO, Inc.
SCTL
0001450325
Lake Ryan David
C/O SOCIETAL CDMO, INC.
1 E. UWCHLAN AVE, SUITE 112
EXTON
PA
19341
0
1
0
0
Chief Financial Officer
Common Stock
2023-01-19
4
A
0
84848
A
596116
D
Common Stock
2023-01-19
4
F
0
28374
1.35
D
567742
D
Common Stock
2023-01-19
4
A
0
230944
0.00
A
798686
D
Common Stock
2023-01-20
4
F
0
14438
1.36
D
784248
D
Stock Option (Right to Buy)
1.35
2023-01-19
4
A
0
160929
0.00
A
2033-01-19
Common Stock
160929
160929
D
On January 19, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 84,848 performance-based restricted stock units granted in a prior year, which were converted into 84,848 shares of common stock on a one-for-one basis.
Shares withheld by the Company to satisfy applicable withholding taxes upon vesting of the performance-based restricted stock units.
Subject to shareholders approving an increase in the number of authorized shares of common stock at the Company's 2023 annual meeting of shareholders, these restricted stock units will vest in four equal annual installments beginning on January 19, 2024, subject to continued service with the Company.
Shares withheld by the Company to satisfy applicable withholding taxes upon vesting of restricted stock units.
Subject to shareholders approving an increase in the number of authorized shares of common stock at the Company's 2023 annual meeting of shareholders, the stock option vests in equal monthly installments over 48 months, beginning on February 19, 2023, subject to continued service with the Company.
/s/ Ryan D. Lake
2023-01-23